Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2003
11/06/2003WO2003091226A1 Triazole derivatives as tachykinin receptor antagonists
11/06/2003WO2003091225A1 Substituted pyrazine derivatives
11/06/2003WO2003091223A1 Pyrimidine derivative
11/06/2003WO2003091215A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003WO2003091214A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
11/06/2003WO2003091204A1 Phenethanolamine derivatives
11/06/2003WO2003090912A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
11/06/2003WO2003090870A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
11/06/2003WO2003090788A1 DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
11/06/2003WO2003090779A1 Remedy for lung cancer
11/06/2003WO2003090769A1 Preparation containing a mixture of picrorrhiza and ginkgo for the relief of disease
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090734A1 Tolterodine salts
11/06/2003WO2003090726A2 Chewable soft capsule
11/06/2003WO2003090715A2 Particulate materials
11/06/2003WO2003090704A1 Foods having effect of eliminating bad breath
11/06/2003WO2003090682A2 Treatment and prevention of pulmonary conditions
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055983A3 Targeted retrograde gene delivery to motor neurons
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
11/06/2003WO2003011327A3 Secretin for the treatment of asthma
11/06/2003WO2003009855A3 Organo-phosphorous compounds for activating gamma/delta t cells
11/06/2003WO2003008564A3 Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002066429A8 Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby
11/06/2003WO2002062945A3 Compositions and methods relating to lung specific genes and proteins
11/06/2003WO2002060900A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002046389A9 Genes associated with allergic hypersensitivity and mast cell activation
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2001080633A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003WO2000023569A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207911 For treatment of disease associated with the adenosine A2 receptor such as Alzheimer's disease and Parkinson's disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207900 2-substituted amino-bicyclic pyridine and pyrimidine compounds; for treatment of inflammation, inflammatory bowel disease, Alzheimer's disease, Crohn's disease, multiple sclerosis and asthma
11/06/2003US20030207892 Heterocyclic amines such as N-(Pyridin-4-yl)-(1-(4-fluoro-benzyl)indol-3-yl)glyoxylamide, used for prophylaxis of skin disorders, rheumatic diseases or arthritis
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207794 Compounds which are alpha -halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207293 Cryptic-like secreted protein
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206868 Immune response modifier compounds for treatment of th2 mediated and related diseases
11/06/2003US20030205229 Drug delivery apparatus
11/06/2003CA2484089A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483980A1 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483306A1 Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
11/06/2003CA2483265A1 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483106A1 Decoys for treating and/or preventing th2 cytokine-related allergic diseases, gata3 mutant proteins and, pharmaceutical compositions comprising the decoys and the proteins
11/06/2003CA2483102A1 Treatment and prevention of pulmonary conditions
11/06/2003CA2483092A1 Tolterodine salts
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2482455A1 1,2,3,4,7,8-hexahydro-6h-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
11/06/2003CA2480845A1 Adipocyte complement related protein zacrp8
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/05/2003EP1359159A2 Analogues of GLP-1
11/05/2003EP1358885A1 Antiallergic agents
11/05/2003EP1358328A2 Regulation of human serotonin-like g protein-coupled recepter
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358189A1 Process for the preparation of a pyrazolo 4,3-d]pyrimidine derivative
11/05/2003EP1358188A2 Antagonists of mcp-1 function and methods of use thereof
1 ... 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 ... 878